Klivira
Request demo

Streamlining Medicare Biktarvy Prior Authorization

Managing Medicare Biktarvy prior authorization is complex, involving distinct pathways for Original Medicare and Medicare Advantage Part D plans. Klivira streamlines this process, ensuring accurate submissions and reducing administrative burden.

For high-volume medications like Biktarvy, an antiretroviral used in HIV-1 treatment, efficient prior authorization is critical for patient access and revenue cycle integrity. Healthcare organizations face the challenge of navigating varied Medicare PA requirements, from MAC-specific medical necessity reviews to Part D formulary adherence. Optimizing this workflow is essential for minimizing denials and accelerating therapy initiation.

Biktarvy and Medicare Coverage Landscape

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a widely prescribed single-pill regimen for HIV-1 infection. Under Medicare, coverage for Biktarvy primarily falls under Part D, administered by private plans. While Original Medicare (Parts A and B) has limited PA scope for medical services, Medicare Advantage (MA) plans and Part D plans frequently implement prior authorization, step therapy, and quantity limits for prescription drugs.

Navigating Medicare Part D Prior Authorization for Biktarvy

Medicare Part D plans, operated by commercial insurers, establish their own formularies and utilization management criteria for drugs like Biktarvy, all approved by CMS. These plans often require prior authorization to ensure medical necessity, adherence to step-therapy protocols, and appropriate dosing. Klivira integrates with these diverse Part D plan requirements, supporting compliant submissions.

Understanding Policy Access: NCDs, LCDs, and Part D Formularies

For any medical service under Original Medicare, National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs) define medical necessity. For Biktarvy under Part D, policies are driven by the specific plan's formulary and utilization management guidelines. Our platform incorporates NCD/LCD-aware logic and adapts to plan-specific Part D requirements.

Key Considerations for Biktarvy PA under Medicare

  • Distinguish between Original Medicare's limited PA scope and the more extensive requirements of Medicare Advantage and Part D plans.
  • Identify the specific Part D plan's formulary tier and utilization management rules for Biktarvy.
  • Ensure documentation supports medical necessity per NCDs, LCDs, or Part D plan criteria.
  • Leverage electronic prior authorization (ePA) channels for faster processing.
  • Understand the specific MAC contractor (e.g., Noridian, NGS, WPS) for any related medical service PA under Original Medicare.

Klivira's Approach to Medicare Biktarvy Prior Authorization

Klivira automates the submission process for Biktarvy, connecting to the relevant Part D plan portals and, where applicable, MAC-jurisdiction channels for associated medical services. Our platform streamlines the collection of clinical data, applies NCD/LCD-aware policy logic, and routes requests through appropriate ePA pathways, reducing manual effort and potential delays for HIV-1 treatment.

Frequently asked questions

Does Original Medicare (Parts A & B) require prior authorization for Biktarvy?

No, Biktarvy is a prescription drug primarily covered under Medicare Part D. Original Medicare has a limited scope for prior authorization, mainly for specific medical services, not typically for outpatient prescription drugs.

How do Medicare Advantage plans handle Biktarvy prior authorization?

Medicare Advantage (MA) plans often include Part D coverage and typically require prior authorization for high-cost or specialty drugs like Biktarvy. Requirements vary by plan, including specific formularies, step therapy, and quantity limits, all approved by CMS.

What documentation is typically needed for Biktarvy prior authorization under Medicare Part D?

Required documentation generally includes confirmation of HIV-1 diagnosis, patient history, previous treatment regimens, and clinical rationale for Biktarvy use. This information must align with the specific Part D plan's medical necessity criteria.

Which entities are responsible for processing Biktarvy PAs under Medicare?

For Part D, the specific commercial insurer operating the Part D plan (or its contracted PBM) processes the PA. For any related medical services under Original Medicare, the relevant Medicare Administrative Contractor (MAC) such as Palmetto or Novitas would be responsible.

How does Klivira help with Biktarvy PA for Medicare patients?

Klivira automates the submission process by integrating with Part D plan portals and MAC-jurisdiction channels. Our system applies relevant policy logic (NCDs, LCDs, Part D formularies) and facilitates the electronic submission of required clinical documentation, reducing manual tasks and accelerating approvals.

Related coverage

Other biktarvy prior authorization by payer

Other biktarvy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo